Cargando…
Personalized (N-of-1) Trials for Patient-Centered Treatments of Multimorbidity
Treatment of patients who suffer from concurrent health conditions is not well served by (1) evidence-based clinical guidelines that mainly specify treatment of single conditions and (2) conventional randomized controlled trials (RCTs) that identify treatments as safe and effective on average. Clini...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673634/ https://www.ncbi.nlm.nih.gov/pubmed/38009131 http://dx.doi.org/10.1162/99608f92.d99e6ff5 |
_version_ | 1785149625148112896 |
---|---|
author | Suls, Jerry M. Alfano, Catherine Yap, Christina |
author_facet | Suls, Jerry M. Alfano, Catherine Yap, Christina |
author_sort | Suls, Jerry M. |
collection | PubMed |
description | Treatment of patients who suffer from concurrent health conditions is not well served by (1) evidence-based clinical guidelines that mainly specify treatment of single conditions and (2) conventional randomized controlled trials (RCTs) that identify treatments as safe and effective on average. Clinical decision-making based on the average patient effect may be inappropriate for treatment of those with multimorbidity who experience burdens and obstacles that may be unique to their personal situation. We describe how the personalized (N-of-1) trials can be integrated with an automatic platform and virtual/remote technologies to improve patient-centered care for those living with multimorbidity. To illustrate, we present a hypothetical clinical scenario—survivors of both coronavirus disease 2019 (COVID-19) and cancer who chronically suffer from sleeplessness and fatigue. Then, we will describe how the four standard phases of conventional RCT development can be modified for personalized trials and applied to the multimorbidity clinical scenario, outline how personalized trials can be adapted and extended to compare the benefits of personalized trials versus between-subject trial design, and explain how personalized trials can address special problems associated with multimorbidity for which conventional trials are poorly suited. |
format | Online Article Text |
id | pubmed-10673634 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
record_format | MEDLINE/PubMed |
spelling | pubmed-106736342023-11-24 Personalized (N-of-1) Trials for Patient-Centered Treatments of Multimorbidity Suls, Jerry M. Alfano, Catherine Yap, Christina Harv Data Sci Rev Article Treatment of patients who suffer from concurrent health conditions is not well served by (1) evidence-based clinical guidelines that mainly specify treatment of single conditions and (2) conventional randomized controlled trials (RCTs) that identify treatments as safe and effective on average. Clinical decision-making based on the average patient effect may be inappropriate for treatment of those with multimorbidity who experience burdens and obstacles that may be unique to their personal situation. We describe how the personalized (N-of-1) trials can be integrated with an automatic platform and virtual/remote technologies to improve patient-centered care for those living with multimorbidity. To illustrate, we present a hypothetical clinical scenario—survivors of both coronavirus disease 2019 (COVID-19) and cancer who chronically suffer from sleeplessness and fatigue. Then, we will describe how the four standard phases of conventional RCT development can be modified for personalized trials and applied to the multimorbidity clinical scenario, outline how personalized trials can be adapted and extended to compare the benefits of personalized trials versus between-subject trial design, and explain how personalized trials can address special problems associated with multimorbidity for which conventional trials are poorly suited. 2022 2022-09-08 /pmc/articles/PMC10673634/ /pubmed/38009131 http://dx.doi.org/10.1162/99608f92.d99e6ff5 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution (CC BY 4.0) International license, except where otherwise indicated with respect to particular material included in the article. |
spellingShingle | Article Suls, Jerry M. Alfano, Catherine Yap, Christina Personalized (N-of-1) Trials for Patient-Centered Treatments of Multimorbidity |
title | Personalized (N-of-1) Trials for Patient-Centered Treatments of Multimorbidity |
title_full | Personalized (N-of-1) Trials for Patient-Centered Treatments of Multimorbidity |
title_fullStr | Personalized (N-of-1) Trials for Patient-Centered Treatments of Multimorbidity |
title_full_unstemmed | Personalized (N-of-1) Trials for Patient-Centered Treatments of Multimorbidity |
title_short | Personalized (N-of-1) Trials for Patient-Centered Treatments of Multimorbidity |
title_sort | personalized (n-of-1) trials for patient-centered treatments of multimorbidity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673634/ https://www.ncbi.nlm.nih.gov/pubmed/38009131 http://dx.doi.org/10.1162/99608f92.d99e6ff5 |
work_keys_str_mv | AT sulsjerrym personalizednof1trialsforpatientcenteredtreatmentsofmultimorbidity AT alfanocatherine personalizednof1trialsforpatientcenteredtreatmentsofmultimorbidity AT yapchristina personalizednof1trialsforpatientcenteredtreatmentsofmultimorbidity |